Ipsen/Inspiration’s Coagulation Factor IX Accepted For Review By EMA
This article was originally published in The Pink Sheet Daily
Executive Summary
As the two firms try to launch a hemophilia B therapy to compete with Pfizer’s BeneFix, EMA acceptance triggers $35 million milestone payment to Inspiration.